María Eugenia Zarabozo

Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain.

Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid.

GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.

Iproteos SL engages in research and development for schizophrenia treatment. It specializes in the research and development of third-generation drugs for human diseases. The company was founded by Ernest Giralt and Teresa Tarragó and is headquartered in Barcelona, Spain.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Ability Pharmaceuticals SL operates as a clinical stage drug discovery and development biopharmaceutical firm. It develops human therapeutics to treat cancer and other indications with unmet medical needs. The company was founded by Carles Domènech Garcia Jordi Espadaler Mazo in November 2009 and is headquartered in Barcelona, Spain.

Inveready Asset Management SGEIC SA (Inveready) is a private equity and venture capital subsidiary of Inveready Capital Co. SL founded in 2008 by Joseph Maria Echarri Torres. The firm is headquartered in San Sebastian, Spain.

AmacaThera, Inc. is biotechnology company, which engages in the development and commercialization of injectable hydrogel platform technology. Its platform addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. The company was founded by Molly S. Soichet and Mike Cooke and is headquartered in Toronto, Canada.

Oxolife SL operates as an biotech company focused on treating female infertility. The company was founded by Agn?s Arbat and Ignasi Canals in 2013 and is headquartered in Barcelona, Spain.

Biotechnology Development for Industry in Pharmaceuticals SL provides biotechnology solutions to the health and food sectors. Its products include vaccine in animal health, and human health products. It also offers product development, process development, and contract manufacturing services. The company is headquartered in Boecillo, Spain.

Zera Intein Protein Solutions SL develops and commercializes biomedical technologies, with applications in the biotechnological, pharmaceutical, veterinary and industrial sectors. Its proprietary technologies include Zera and Splittera. Zera technology is composed of self-assembler peptides for DNA vaccines, carrier-free enzyme immobilization, and biopharmaceutical protein production. Splittera refers to Split Intein technology which includes trans-splicing, cyclization, and cleavage reactions. The company was founded on January 30, 2015 and is headquartered in Barcelona, Spain.

Agrasys SL develops and commercialize crops and cereals. It offers Tritordeum, a non genetic modification cereals and developed for human nutrition. The company was founded in 2005 and is headquartered in Barcelona, Spain.

InnoUp Farma SL develops nanotechnology-based solutions for the administration of oral drugs. It offers anti-cancer drugs with low oral bioavailability. The company was founded by Maite Agueros Bazo, Manuel Rodriguez Mariscal and Juan Manuel Irache Garreta and is headquartered in Noain, Spain.

Antalgenics SL is a Spanish biotechnological company that specializes in discovering and developing new bioactive molecules for biomedical and dermocosmetic applications. The company is based in Alicante, Spain. The company offers customized R & D services to design and develop projects according to the client's needs. The company's focus is on developing novel therapeutic leads, primarily for the treatment of psoriatic pruritus and psoriatic comorbidities. Antalgenics was founded in 2015, and the CEO is Philipp Tsolakis.

Connecta Therapeutics SL is an innovation-oriented, R&D-intensive organization committed to developing innovative treatments for patients. Connecta Therapeutics is based in Barcelona, ES. The Spanish company strongly believes in improving the lives of patients and their families and understands the importance of teamwork and collaboration to achieve their goals. The company was founded in 2019 by Josep Prous, David Prous, and Jordi Fàbrega. Jordi Fàbrega has been the CEO since 2019.

Avizorex Pharma SL develops drugs for the treatment of the dry eye disease. The company was founded by Carlos Belmonte and Sauri Patrick Tresserras in July, 2013 and is headquartered in Barcelona, Spain.